Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 128

Results For "CROs"

3863 News Found

Apollo signs agreement to manage internal security force hospital in Iraq
Healthcare | September 29, 2025

Apollo signs agreement to manage internal security force hospital in Iraq

The collaboration is expected to facilitate access to world-class treatments and specialised care for Iraqi personnel


Infinitus launches MCP server to bring standardized AI interoperability to healthcare
Digitisation | September 29, 2025

Infinitus launches MCP server to bring standardized AI interoperability to healthcare

New infrastructure makes it possible for healthcare organizations to integrate AI agents seamlessly into critical workflows like benefit verification and prior authorization


Moderna opens manufacturing and R&D facility in UK
News | September 27, 2025

Moderna opens manufacturing and R&D facility in UK

The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population


Bartronics India acquires 15% stake in Huwel Life Sciences for Rs. 50 Cr
News | September 26, 2025

Bartronics India acquires 15% stake in Huwel Life Sciences for Rs. 50 Cr

BIL also holds an option to increase its equity stake by an additional 15%


Pi Health to deliver clinical research services for  GSK’s Phase 2 oncology trial
News | September 26, 2025

Pi Health to deliver clinical research services for GSK’s Phase 2 oncology trial

Physician-led Pi Health has demonstrated capabilities to dramatically reduce clinical trial timelines and administrative burden, while increasing data quality


AstraZeneca’s Koselugo recommended for approval in the EU for Neurofibromatosis type 1
Drug Approval | September 24, 2025

AstraZeneca’s Koselugo recommended for approval in the EU for Neurofibromatosis type 1

The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population